Adagene to Present at Upcoming Investor Conferences

Rhea-AI Summary

Adagene Inc. (Nasdaq: ADAG), a clinical-stage biopharmaceutical company, announced that its CEO, Peter Luo, Ph.D., will present at two upcoming conferences: the Jefferies Virtual Healthcare Conference on June 4, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. At these events, Adagene will discuss its innovative approaches in antibody-based cancer immunotherapies using its proprietary DPL platform, which includes NEObody, SAFEbody, and POWERbody technologies.

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021 and the Goldman Sachs 42^nd Annual Global Healthcare Conference to be held June 8-11, 2021.

Details on the presentations can be found below.

Jefferies Virtual Healthcare Conference
Date: Friday, June 4, 2021
Presentation Time: 10:00 AM ET
Webcast: Click Here

Goldman Sachs 42^nd Annual Global Healthcare Conference
Date: Thursday, June 10, 2021
Presentation Time: 5:30 PM ET
Webcast: Click Here

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

Investors Contact:
Raymond Tam
Adagene
86-512-8777-3626
ir@adagene.com

Bruce Mackle
LifeSci Advisors
646-889-1200
bmackle@lifesciadvisors.com

Media Contact:
Annie Starr
6 Degrees
973-768-2170
astarr@6degreespr.com

FAQ

What is the date of Adagene's presentation at the Jefferies Virtual Healthcare Conference?

Adagene will present on June 4, 2021.

When is Adagene presenting at the Goldman Sachs 42nd Annual Global Healthcare Conference?

Adagene's presentation is scheduled for June 10, 2021.

Who is the CEO of Adagene?

Peter Luo, Ph.D., is the CEO of Adagene.

What technology does Adagene utilize for its immunotherapy programs?

Adagene uses its proprietary DPL platform, which includes NEObody, SAFEbody, and POWERbody technologies.

What is the stock symbol for Adagene?

Adagene is traded under the stock symbol ADAG.